Miller Barbra S, Else Tobias
Endocr Pract. 2017 Jun;23(6):705-715. doi: 10.4158/EP161719.RA.
A concerted effort has been made in the past decade to better differentiate benign from malignant adrenocortical tumors. Of those tumors found to be adrenocortical carcinomas (ACCs) and through the use of multiple modalities including biochemical, radiologic, and genomic analysis, significant strides have been made in understanding what drives ACC development, how various treatments may result in different outcomes, which ACCs are more likely to respond to various treatments, and overall prognosis. While most patients will have recurrence of their ACC and succumb to their disease, the disease course is highly variable; it is therefore imperative that each patient is treated with individualized attention paid to their particular ACC. This article highlights and discusses specific, important, and many times subtle features that may impact the evaluation, management, treatment selection, and outcome of patients with ACC.
ACC = adrenocortical carcinoma; CT = computed tomography; XRT = external beam radiation therapy.
在过去十年中，人们齐心协力，以更好地区分良性和恶性肾上腺皮质肿瘤。在那些被发现为肾上腺皮质癌（ACC）的肿瘤中，通过使用包括生化、放射学和基因组分析在内的多种方法，在理解驱动ACC发展的因素、各种治疗如何导致不同结果、哪些ACC更可能对各种治疗产生反应以及总体预后方面取得了重大进展。虽然大多数ACC患者会复发并死于该疾病，但病程差异很大；因此，必须对每位患者进行个体化治疗，并关注其特定的ACC。本文重点介绍并讨论了可能影响ACC患者评估、管理、治疗选择和预后的具体、重要且往往细微的特征。
ACC = 肾上腺皮质癌；CT = 计算机断层扫描；XRT = 外照射放疗
